TY - JOUR
KW - Antidepressive Agents, Tricyclic/therapeutic use
KW - Depressive Disorder, Major/complications/drug therapy/epidemiology
KW - Female
KW - Humans
KW - Male
KW - Patient-Centered Care/organization & administration
KW - Serotonin Uptake Inhibitors/therapeutic use
KW - Somatoform Disorders/drug therapy/etiology/physiopathology
KW - Suicide
KW - Treatment Outcome
KW - United States/epidemiology
AU - C. B. Ticknor
A1 - 
AB - OBJECTIVE: To review the tricyclic antidepressants, selective serotonin reuptake inhibitors, and dually acting antidepressants and their economic and treatment implications. SUMMARY: Major depressive disorder.s cost to the U.S. economy is staggering, but the selection of drugs available to treat it has expanded to include drugs that have better side-effect profiles. Regardless, remission rates are high, and, often, patients are not treated aggressively enough. Somatic presentations are more common than previously thought, and pain, in particular, may be associated with depression. Pain and depression are both regulated by serotonin and norepinephine, and several studies suggest that using dual-action antidepressants may be helpful in patients who have an element of pain to their disorder. Titration to an adequate dose of any antidepressant is important, as is sustaining treatment for months to years, depending on the patient.s history. CONCLUSION: Increasingly, the mental health community is realizing that the goal of treatment for patients with major depressive disorder must be sustained remission.
BT - Journal of managed care pharmacy : JMCP
C5 - Medically Unexplained Symptoms
CP - 2 Suppl
CY - United States
IS - 2 Suppl
JF - Journal of managed care pharmacy : JMCP
N2 - OBJECTIVE: To review the tricyclic antidepressants, selective serotonin reuptake inhibitors, and dually acting antidepressants and their economic and treatment implications. SUMMARY: Major depressive disorder.s cost to the U.S. economy is staggering, but the selection of drugs available to treat it has expanded to include drugs that have better side-effect profiles. Regardless, remission rates are high, and, often, patients are not treated aggressively enough. Somatic presentations are more common than previously thought, and pain, in particular, may be associated with depression. Pain and depression are both regulated by serotonin and norepinephine, and several studies suggest that using dual-action antidepressants may be helpful in patients who have an element of pain to their disorder. Titration to an adequate dose of any antidepressant is important, as is sustaining treatment for months to years, depending on the patient.s history. CONCLUSION: Increasingly, the mental health community is realizing that the goal of treatment for patients with major depressive disorder must be sustained remission.
PP - United States
PY - 2004
SN - 1083-4087; 1083-4087
EP - 15
EP - S8+
T1 - Pharmacologic considerations in treating depression: a patient-centered approach
T2 - Journal of managed care pharmacy : JMCP
TI - Pharmacologic considerations in treating depression: a patient-centered approach
U1 - Medically Unexplained Symptoms
U2 - 15046545
VL - 10
VO - 1083-4087; 1083-4087
Y1 - 2004
ER -